TrialClinical cancer research : an official journal of the American Association for Cancer Research2016

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Beata Holkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.